Results 171 to 180 of about 24,454 (211)
Some of the next articles are maybe not open access.

Acromegaly

New England Journal of Medicine, 1990
Subcellular mechanisms support the notion of an intrinsic pituitary defect in acromegaly, with elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels that affect the cardiovascular and respiratory system, as well as neoplastic cell proliferative activity.
openaire   +3 more sources

Ectopic Acromegaly

Endocrinology and Metabolism Clinics of North America, 1992
Ectopic acromegaly is a rare syndrome (less than 1% of acromegalic patients) caused by ectopic growth hormone-releasing hormone (GHRH) or growth hormone (GH)-producing tumors. Its recognition is clinically important because acromegaly may be a symptom of an aggressive tumor, and different therapeutic approaches are required.
G. Faglia, M. Arosio, N. Bazzoni
openaire   +3 more sources

ACROMEGALY AND NARCOLEPSY

The Lancet, 1979
7 of 372 acromegalic patients had troublesome episodes of paroxysmal daytime sleep. Although 3 patients had complete remission of symptoms within a few days of pituitary implantation of isotopes, the cause of this increased frequency of narcolepsy among acromegalic patients is not known.
C, Guilleminault, J, van den Hoed
openaire   +5 more sources

Acromegaly

New England Journal of Medicine, 2023
Joshua, Weinreb, Shitij, Arora
openaire   +2 more sources

Acromegaly

2014
Acromegaly is due to excessive production of growth hormone (GH), generally by a pituitary GH-secreting adenoma. Its prevalence is estimated at 40-130 cases per million inhabitants. Acromegaly is characterized by slowly progressive acquired somatic disfigurement (mainly involving the face and extremities) and systemic manifestations. The rheumatologic,
Philippe, Chanson   +2 more
openaire   +2 more sources

Acromegaly and bone

Minerva Endocrinology, 2018
Growth hormone (GH) and insulin-like growth factor-I (IGF-I) have pleiotropic effects on the skeleton throughout the lifespan by influencing bone formation and resorption. Despite these positive effects on skeletal metabolism, in presence of GH and IGF-I excess, bone turnover increases excessively leading to deterioration of bone microarchitecture and ...
Filippo, Maffezzoni, Anna M, Formenti
openaire   +2 more sources

Pathophysiology of Acromegaly*

Endocrine Reviews, 1983
This review discusses the pathophysiology of acromegaly. Acromegaly has been classified in this paper into distinct entities based on etiology, ultrastructural features of the pituitary, and cytogenesis. This classification has been proposed based on clinical signs, immunoperoxidase techniques, transmission electromicroscopy and immunoelectron ...
S, Melmed   +4 more
openaire   +2 more sources

Acromegaly and psoriasis

Clinical and Experimental Dermatology, 1991
A 56-year-old man with long-standing chronic plaque psoriasis was noted to be acromegalic. Investigations confirmed the presence of a large pituitary adenoma and following treatment of this by hypophysectomy his psoriasis cleared dramatically within 3 weeks.
D J, Todd, D J, Eedy, J C, McMillan
openaire   +2 more sources

Epidemiology of Acromegaly

Pituitary, 1999
Acromegaly is a consequence of chronic growth hormone (GH) excess, due in the majority of cases to a GH-secreting pituitary adenoma, and occurring with a population prevalence of 60 per million and an incidence of 3-4 per million per year. Males and females appear to be equally affected with an average age of presentation of 44 years.
I M, Holdaway, C, Rajasoorya
openaire   +2 more sources

The History of Acromegaly

Neuroendocrinology, 2015
Pierre Marie coined the term ‘acromegaly' in 1886 and linked it to a distinct clinical disease with a characteristic clinical picture. However, Pierre Marie was not the first physician to give a full record of the clinical picture of acromegaly; others had preceded him, like the Dutch physician Johannes Wier.
openaire   +2 more sources

Home - About - Disclaimer - Privacy